Date: 2013-12-17
Type of information: Licensing agreement
Compound: Macrocyclic Template Chemistry (MATCH™) discovery platform
Company: Roche (Switzerland) Ocera Therapeutics (USA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: MATCH™ (Macrocyclic Template Chemistry) is based on the development of proprietary small molecule macrocycles. Ocera’s macrocycles are a distinct class of small molecules with defined and predictable shapes. MATCH™ compounds mimic the favorable binding characteristics of proteins and peptides such as tight receptor binding for high potency and selectivity, while eliminating the drawbacks associated with biomolecules such as poor metabolic stability, low oral bioavailability, lack of membrane permeability, high manufacturing costs, and antigenicity. Ocera macrocycles incorporate three recognition moieties locked in a defined, cyclic, three-dimensional structure by a proprietary non-peptide chemical fragment called a tether, having a molecular weight of 100-200. The recognition moieties originate from either natural or non-natural amino acids.
Disease:
Details: * On December 17, 2013, Ocera Therapeutics has announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH™) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH™ technology, and grant a license to Genentech and Roche under Ocera\'s related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Financial terms:
Latest news:
